←
Manni Mohyuddin7,772 posts
Manni Mohyuddin avatar

Manni Mohyuddin

@ManniMD1

Cancer doctor with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. Views own.

◷ Joined June 2020▧ 892 Photos and videos
Manni Mohyuddin avatar
Manni Mohyuddin@ManniMD1·30 Jan 2022

For those that just followed me: I tweet about plasma cell disorders. I feel strongly about end-of-life, medical education and calling out what I feel is wrong (such as bad control arms, hype etc) I write educational 🧵occasionally- compiled here👇 https://t.co/7RpUkh02NX #mmsm

Post attachment
Martin Schoen MD MPH avatar
⟳ Manni Mohyuddin retweeted
Martin Schoen MD MPH@mwschoen·2 Aug 2024

The survival of the control arm was less than contemporary trials of similar agents, which could be from patient selection, lack of blinding, inadequate subsequent care or other unknown factor, better?

Manni Mohyuddin avatar
Manni Mohyuddin@ManniMD1·2 Aug 2024

👌🏽👌🏽👌🏽 To say that belantamab does not impair quality of life is ridiculous. It speaks to the imperfection of how we assess and report quality of life. Unfortunate that some obvious truths have to be clearly pointed out this way. @AaronGoodman33

Shycollie@shycollie2 Aug 2024

For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiting and dangerous. In the real world lots of patients have weird insurance, Medicaid so quick access to top flight ophthalmologists interested in these pts is too limited

Shycollie avatar
⟳ Manni Mohyuddin retweeted
Shycollie@shycollie·2 Aug 2024

For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiting and dangerous. In the real world lots of patients have weird insurance, Medicaid so quick access to top flight ophthalmologists interested in these pts is too limited

レ点🧬💉💊 avatar
⟳ Manni Mohyuddin retweeted
レ点🧬💉💊@m0370·2 Aug 2024

特定の製薬企業から顧問料を受けてアドバイザーを務めている人物がNEJMのように臨床医に影響力を持つ雑誌に論説を寄稿することについての警鐘をした文章。薬剤の有用性ばかりが強調されてQOLを損ねる有害事象などが過小評価されかねない、と。/NEJM

NEJM is the best journal in our field. I did expect a more nuanced editorial and was a little disappointed to see this. Belantamab is indeed defying expectations and turning out to be better than expected. However.... ⭐️The fact that quality of life was not reported as being worse is an indictment of quality of life instruments and reporting (and attrition on their completion rate) rather than belantamab having no effect on quality of life. ⭐️Belantamab isnt quite as convenient and "easy to administer" as the authors listed. Frequent eye exams are inconvenient, and the drug profoundly impacts quality of life in ways instruments don't capture. ⭐️No mention on censoring, and that the control arm (Dara/Velcade/dex) underperformed relative to earlier trials. A last note- shouldnt the NEJM have a policy to not accept editorials from people with consulting payments for the drug in question? I say this in the politest way I can and this is not personal (its a broader problem), but for the integrity of science, we should abstain from writing editorials in top-notch journals for drugs we take personal payments for. nejm.org/doi/pdf/10.1056/NEJ…

Post attachmentPost attachment
Manni Mohyuddin avatar
Manni Mohyuddin@ManniMD1·2 Aug 2024

This study (40 patients each arm) is a good representation of how a small sample size can lead to an unreliable estimate. A PFS difference of 13 months with ixazomib is unlikely to be replicated in phase 3, and inconsistent with what ixa has shown! tinyurl.com/bdex6nxe

Post attachment
Manni Mohyuddin avatar
Manni Mohyuddin@ManniMD1·2 Aug 2024

NEJM is the best journal in our field. I did expect a more nuanced editorial and was a little disappointed to see this. Belantamab is indeed defying expectations and turning out to be better than expected. However.... ⭐️The fact that quality of life was not reported as being worse is an indictment of quality of life instruments and reporting (and attrition on their completion rate) rather than belantamab having no effect on quality of life. ⭐️Belantamab isnt quite as convenient and "easy to administer" as the authors listed. Frequent eye exams are inconvenient, and the drug profoundly impacts quality of life in ways instruments don't capture. ⭐️No mention on censoring, and that the control arm (Dara/Velcade/dex) underperformed relative to earlier trials. A last note- shouldnt the NEJM have a policy to not accept editorials from people with consulting payments for the drug in question? I say this in the politest way I can and this is not personal (its a broader problem), but for the integrity of science, we should abstain from writing editorials in top-notch journals for drugs we take personal payments for. nejm.org/doi/pdf/10.1056/NEJ…

Post attachmentPost attachment
Manni Mohyuddin avatar
Manni Mohyuddin@ManniMD1·1 Aug 2024

Actually, Aaron has many papers/trials too. I am biased, but my favorite paper of his one we wrote together in which we highlighted the epidemic of over-treatment of myeloma and its precursor states. Heres a non paywalled link to it: drive.google.com/file/d/1wPI…

Post attachmentPost attachment

Happy to see this piece on @AaronGoodman33 in @TheLancetHaem. A well deserved accolade. Greatness isn’t defined by the n of papers/trials you have, but by taking good care of pts, and being a great husband/father/friend. And that’s what Aaron is! thelancet.com/journals/lanha…

Post attachmentPost attachment
Dr Amol Akhade avatar
⟳ Manni Mohyuddin retweeted
Dr Amol Akhade@SuyogCancer·31 Jul 2024

You know when Drug is not blockbuster ( or even close to being that ) when it is keep getting defended in repeated correspondence @TheLancetOncol When the Sun 🌞 shines , do we need torch to see it ? Putting both sides . Readers to choose wisely. Any comments @VPrasadMDMPH @Timothee_MD

Post attachmentPost attachmentPost attachmentPost attachment
Anil Makam avatar
⟳ Manni Mohyuddin retweeted
Anil Makam@AnilMakam·30 Jul 2024

Pair this study with this excellent @JAMAInternalMed perspective on the "too fast" bias where groups separate way faster than biologically plausible this is a dead giveaway groups are not the same despite best efforts to adjust @VPrasadMDMPH jamanetwork.com/journals/jam…

Anil Makam@AnilMakam30 Jul 2024

AMAZING!!! The second you whiff semaglutide you immediately have improvement on proxy measures of tobacco use!!! Sarcasm intended since this is a negative outcome - too much confounding Also EHR data cannot speak to smoking cessation Epic fail of peer & editorial review

Anil Makam avatar
⟳ Manni Mohyuddin retweeted
Anil Makam@AnilMakam·30 Jul 2024

AMAZING!!! The second you whiff semaglutide you immediately have improvement on proxy measures of tobacco use!!! Sarcasm intended since this is a negative outcome - too much confounding Also EHR data cannot speak to smoking cessation Epic fail of peer & editorial review

New: Semaglutide may help people quit smoking. A study from @NIDAnews @NIH found that new use of the drug was associated with a lower risk for medical care related to TUD in smokers with type 2 diabetes compared with 7 other anti-diabetes medications: ecs.page.link/81fAY

Samer Al Hadidi, MD,MS,FACP avatar
⟳ Manni Mohyuddin retweeted
Samer Al Hadidi, MD,MS,FACP@HadidiSamer·28 Jul 2024

This is an updated results data of BCMA CAR-T and BCMA BsAb with updated data from recent presentations/publications based on few requests I got #mmsm ✅Updated data for Elranatamab looks great ✅In areas with equal access to CAR-T: no role for ide cel ✅Excellent BsAb data

Post attachment